These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3180070)

  • 21. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of CI-921 in advanced malignancies.
    Sklarin NT; Wiernik PH; Grove WR; Benson L; Mittelman A; Maroun JA; Stewart JA; Robert F; Doroshow JH; Rosen PJ
    Invest New Drugs; 1992 Nov; 10(4):309-12. PubMed ID: 1487405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
    Paxton JW; Jurlina JL
    Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
    Paxton JW; Evans PC; Hardy JR
    Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.
    Stevenson JP; DeMaria D; Reilly D; Purvis JD; Graham MA; Lockwood G; Drozd M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1999; 44(3):228-34. PubMed ID: 10453724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
    Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
    Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
    Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
    Harman GS; Craig JB; Kuhn JG; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J; Tuttle RL; Lucas VS
    Cancer Res; 1988 Aug; 48(16):4706-10. PubMed ID: 3396016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.